 A phase- I clinical trial to determine safety and feasibilty of intravenous administration of mitomycin C-treated donor peripheral blood mononuclear cells in patients with chronic kidney disease stage KDIGO 4 or 5 i.e. GFR 15-30 mLmin or 15 mLmin who receive a kidney transplant from a living donor. 